LATEST NEWS MHRA Approves Phase I/II Clinical Trial of IN3BIO Vaccine to Improve Outcomes for Colorectal Cancer PatientsMarch 10, 2022March 9, 2022 – IN3BIO Research Limited, a leader in developing cancer treatments that, based upon clinical data, show significant…Read More IN3BIO gains approval for Phase I/II clinical trialJune 9, 2021June 8, 2021 – IN3BIO Research Limited announced today that the company has received the Clinical Trial Application approval from…Read More Pangaea Oncology Signs 1.1 Mln contract with In3BIOJuly 9, 2020July 8, 2020 (Reuters) – Pangaea Oncology SA: Source: https://uk.reuters.com/article/idUKL8N2EF4DZRead More